Study drug for active dermatomyositis or polymyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult age 18 or older.
- You have active dermatomyositis or polymyositis that started when you were younger (age of onset required).
- You are on a steady (not changing) dose of standard care medicines at the time you enroll.
- Your muscle disease is idiopathic inflammatory myopathy (not caused by other specific myositis types).
- You do not have certain serious infections or recent hospitalization for serious infection within the last 60 days.
- You do not have recent or current cancer (within 5 years), major recent heart/stroke events, certain major surgeries, or high-risk immune/neurologic conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
This study tests whether adding a new anti-inflammatory drug (Maraviroc) to your current treatment can better control active myositis (inflammatory muscle disease) when other treatments have not worked well enough.
This study tests a new oral medication, nerandomilast, for people with active idiopathic inflammatory myopathies (a group of rare autoimmune diseases causing muscle weakness). It aims to see if the drug can reduce disease activity safely. Participants must have moderate-to-severe symptoms and be on standard treatments.
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
This trial is testing an investigational medicine called PF-08154225 for people with autoimmune diseases like rheumatoid arthritis, lupus, myositis, or systemic sclerosis. It aims to see if the drug is safe and effective in reducing disease activity.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.